Oct
2026
Fiera Milano, Italy
Visit us
stand 20K18, Finished Dosage & Formulation

PENMIX Co. Ltd.

Exhibitor at CPHI Milan 2026
About Us

PPENMIX is a specialized CDMO with proven expertise in Pen Injector development and manufacturing, covering the entire process from research planning and development to licensing and commercial production. With dedicated in-house R&D and Regulatory Affairs specialists, we provide reliable and efficient project management for global partners.
We are certified by PMDA, K-GMP, and are preparing for EU GMP and cGMP compliance, with the goal of entering the EU & U.S.2027.

Read more Show less
Sales Markets
Show more Show less
Categories
more categories Show less
  • Country/Region:
    Korea, Republic Of
  • On CPHI since:
    2015
  • Certificates:
    2
  • Employees:
    250 - 499
Company types
CMO/CDMO
Contract Service
Pharmaceutical company
Primary activities
Contract Manufacturer
Pharmaceutical Company (generic finished products)
View company profile
Contact info
  • 82-2-2175-9848
  • Ohsong Blgd, 14 Jeongdong-gil, , 100-120, Jung-gu, Seoul, Korea, Republic Of
Show contact info Hide contact info
Event information
CPHI Milan 2026
  • 6 Oct 2026 - 8 Oct 2026
  • Fiera Milano, Italy
  • Visit us at stand 20K18, Finished Dosage & Formulation

Products Featured at CPHI Milan 2026

  • Daptomycin

    Product Daptomycin

    For treatment of bloodstream infection (bacteremia) associated with right infective endocarditis caused by Staphylococcus aureus(including methicillin sensitivity and methicillin resistance).
  • Ferric Carboxymaltose

    Product Ferric Carboxymaltose

    Under development for global market
  • Sugammadex

    Product Sugammadex

    200mg/2mL500mg/5mL
  • Liraglutide

    Product Liraglutide

    It is a generic version of Saxenda. Development has been completed, and we are currently seeking partners for its launch in Europe.
  • Semaglutide

    Product Semaglutide

    This is a generic version of Wegovy. 

    Development has been completed, and we plan to launch it as the first generic in Europe once the market exclusivity period expires. 


    We are currently seeking partners to collaborate on this objective.